Genomtec S.A. (FRA:4VI)

Market Cap	10.68M -51.5%
Revenue (ttm)	8.14K +218.2%
Net Income	-1.85M
EPS	-0.11
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Open	0.5920
Previous Close	0.5780
Day's Range	0.5650 - 0.5920
52-Week Range	0.5200 - 1.5000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Genomtec

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that enables the detection of pathogens, such as viruses, bacteria, and fungi, as well as genetic mutations through the analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detectio...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Employees: 32
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4VI

Financial Performance

In 2025, Genomtec's revenue was 19,000, an increase of 1800.00% compared to the previous year's 1,000. Losses were -10.22 million, -8.80% less than in 2024.

Financial numbers in PLN

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error